Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Aromatase Inhibitor
37%
Metastatic Breast Cancer
33%
Solid Malignant Neoplasm
28%
Neoplasm
24%
Tolerability
24%
Hormone Receptor
22%
Chemotherapy
22%
Triple Negative Breast Cancer
20%
Disease
19%
Endocrine Therapy
17%
Pharmacokinetics
15%
Progression Free Survival
14%
Biological Marker
12%
Arthralgia
12%
Carbonate Dehydratase IX
11%
Adverse Event
11%
Cyclophosphamide
10%
Exemestane
10%
Arthritis
10%
Paclitaxel
10%
Sunitinib
10%
Doxorubicin
10%
Maximum Tolerated Dose
9%
Granulocyte Colony Stimulating Factor
9%
Bavituximab
9%
Fulvestrant
9%
Sulindac
9%
Carcinomatous Meningitis
9%
Etoposide
9%
Irinotecan
9%
Programmed Death 1 Ligand 1
9%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
9%
Epidermal Growth Factor Receptor
9%
Carpal Tunnel Syndrome
9%
Tucatinib
9%
Naphthalimide Derivative
9%
Musculoskeletal Disease
9%
Abemaciclib
9%
Mitomycin
9%
Aeg 35156
9%
Pancreas Adenocarcinoma
9%
Diethylstilbestrol
9%
Oxylipin
9%
Eribulin
9%
Metastatic Melanoma
9%
Antiangiogenic Therapy
9%
Inflammatory Breast Cancer
9%
Lobular Carcinoma
9%
Taxane
8%
Medicine and Dentistry
Breast Cancer
66%
Aromatase Inhibitor
29%
Neoplasm
27%
Malignant Neoplasm
22%
Biological Marker
21%
Symptom
19%
Chemotherapy
18%
Breast Density
18%
Randomized Controlled Trial
18%
Arthralgia
18%
Western Ontario and McMaster Universities Osteoarthritis Index
14%
Magnetic Resonance Imaging
14%
Metastatic Breast Cancer
14%
BRCA2
14%
Quality of Life
13%
Postmenopause
13%
Primary Health Care
12%
Hormone Receptor
12%
Breast Cancer Prevention
12%
Symptom Management
12%
Cancer Therapy
11%
DNA Repair
10%
Glycon
9%
Bavituximab
9%
Distress Syndrome
9%
Supportive Care
9%
Acidosis
9%
Pathophysiology
9%
Sulindac
9%
Epidermal Growth Factor Receptor
9%
Carbonate Dehydratase IX
9%
Mitomycin
9%
Breast Tumor
9%
Health Service
9%
Thrombotic Thrombocytopenic Purpura
9%
Abemaciclib
9%
Transcranial Magnetic Stimulation
9%
Tucatinib
9%
Pancreas Adenocarcinoma
9%
Aeg 35156
9%
Obesity
9%
Shear Wave Elastography
9%
Nonsteroid Antiinflammatory Agent
9%
Oxylipin
9%
Antiangiogenic Therapy
9%
Metabolic Syndrome
9%
Lobular Carcinoma
9%
Survivorship in Cancer Care
7%
BRCA1
7%
Hormone Therapy
7%
Keyphrases
Breast Cancer
38%
Randomized Controlled Trial
19%
Aromatase Inhibitor-induced Arthralgia
18%
Metformin
18%
Cancer Survivors
15%
Stiffness
14%
Survivors
14%
Caregivers
12%
WOMAC
11%
Obesity
11%
Social Determinants of Health (SDoH)
10%
Breast Cancer Patients
10%
Informal Caregivers
10%
Breast Density
10%
Psychological Symptoms
10%
Breast Cancer Risk
10%
Breast Cancer Prevention
10%
Musculoskeletal Symptoms
9%
Telephone
9%
Health Burden
9%
Cancer Treatment
9%
Bavituximab
9%
HER2-negative Metastatic Breast Cancer
9%
Health Service Use
9%
Rare Tumors
9%
Breast Cancer Survivors
9%
Copy number Variation
9%
Sulindac
9%
Intervention Effect
9%
Germ Cells
9%
Correction Dose
9%
Antiangiogenic Therapy
9%
Whole Exome Sequencing
9%
Urogenital Symptoms
9%
Extended Interval Dosing
9%
Estrogen Receptor-positive Metastatic Breast Cancer
9%
Exemestane
9%
Adiposity
9%
Visual Rating
9%
BAY 94-9027
9%
Carbonic Anhydrase IX
9%
UNBS5162
9%
Supportive Care Intervention
9%
Prevention Trials
9%
Taiwanese Women
9%
Dyadic Interdependence
9%
Aromatase Inhibitors
9%
Phase II Study
9%
Sunitinib Malate
9%
Metabolic Syndrome Components
9%
